GILD34:BVMF
Gilead Sciences Inc BDR
65,81 BRL
0,00%
(0,00) 1 zi
16 oct., 16:56:00 GMT-3 · BRL
search
Toate simbolurile
| Simbol | Preț | Modificare | Modificare % |
|---|
insights_autoSe generează principalele statistici pentru GILD34...
Deschide
66,36 BRL
Mare
66,41 BRL
Mic
65,81 BRL
Capitalizarea bursieră
193,67 mld.
Volum mediu
261,00
Volum
1,78 K
Prețul ridicat pe 52 de săptămâni
67,38 BRL
Prețul redus pe 52 de săptămâni
51,33 BRL
Acțiuni aflate în circulație
1,24 mld.
Nr. de angajați
17 K
Deschide
66,36 BRL
Mare
66,41 BRL
Mic
65,81 BRL
Capitalizarea bursieră
193,67 mld.
Volum mediu
261,00
Volum
1,78 K
Prețul ridicat pe 52 de săptămâni
67,38 BRL
Prețul redus pe 52 de săptămâni
51,33 BRL
Acțiuni aflate în circulație
1,24 mld.
Nr. de angajați
17 K
Subiecte de știri
Din surse web și de la parteneri de știri
Yahoo Finance
·
acum 6 ore
Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow?
ad-hoc-news.de
·
acum 7 ore
Gilead Sciences stock trades 0.32 percent above its Xetra close
Simply Wall Street
·
acum 1 zi
Did Cancer Drug Partnership Just Shift Gilead's (GILD) Investment Narrative?
MarketBeat
·
acum 1 zi
Gilead Sciences, Inc. $GILD Stock Sold by New England Research & Management Inc.
Profil
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Despre Gilead Sciences Inc BDR
Director executivDaniel O'Day
Angajați17 K
Înființată la22 iun. 1987
SediuFoster City, California, Statele Unite ale Americii
Domeniu-
Sitegilead.com